Invesco Nasdaq Biotechnology ETF(IBBQ · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$29.60
- 52-Week Range
- $20.67 – $30.50
- YTD
- +4.31%
- IV Rank (30D)
- 33.18
- Straddle Price
- $2.22
Info
Invesco Nasdaq Biotechnology ETF (IBBQ) ETF
- Exchange
- XNAS
- Inception
- 2021-06-11
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-11
Holdings
260
AUM
$66.6M
Provider
Invesco
Inception
2021-06-11
Exchange
XNAS
Data As Of
2026-06-11
Expense Ratio
—
Dividend Yield
0.85%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-23 | 2026-03-27 | $0.0361 | CD |
| 2025-12-22 | 2025-12-26 | $0.0906 | CD |
| 2025-09-22 | 2025-09-26 | $0.0958 | CD |
| 2025-06-23 | 2025-06-27 | $0.0287 | CD |
| 2025-03-24 | 2025-03-28 | $0.0402 | CD |
| 2024-12-23 | 2024-12-27 | $0.0619 | CD |
Asset Allocation
Top Holdings
top 50 of 260 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc | 7.56% | Equity (US) | — |
| VRTX | Vertex Pharmaceuticals Inc | 7.42% | Equity (US) | — |
| GILD | Gilead Sciences Inc | 7.00% | Equity (US) | — |
| REGN | Regeneron Pharmaceuticals Inc | 5.12% | Equity (US) | — |
| ALNY | Alnylam Pharmaceuticals Inc | 3.09% | Equity (US) | — |
| RVMD | Revolution Medicines Inc | 2.38% | Equity (US) | — |
| BIIB | Biogen Inc | 2.36% | Equity (US) | — |
| ARGX | Argenx SE | 2.05% | Cash/Money Market | — |
| ILMN | Illumina Inc | 2.05% | Equity (US) | — |
| UTHR | United Therapeutics Corp | 1.93% | Equity (US) | — |
| RPRX | Royalty Pharma PLC | 1.91% | Equity (US) | — |
| INCY | Incyte Corp | 1.73% | Equity (US) | — |
| ROIV | Roivant Sciences Ltd | 1.72% | Equity (US) | — |
| INSM | Insmed Inc | 1.68% | Equity (US) | — |
| MRNA | Moderna Inc | 1.58% | Equity (US) | — |
| VTRS | Viatris Inc | 1.53% | Equity (US) | — |
| GH | Guardant Health Inc | 1.38% | Equity (US) | — |
| NBIX | Neurocrine Biosciences Inc | 1.32% | Equity (US) | — |
| JAZZ | Jazz Pharmaceuticals PLC | 1.17% | Equity (US) | — |
| EXEL | Exelixis Inc | 1.12% | Equity (US) | — |
| MEDP | Medpace Holdings Inc | 1.09% | Equity (US) | — |
| ASND | Ascendis Pharma A/S | 1.07% | Equity (US) | — |
| BBIO | Bridgebio Pharma Inc | 1.06% | Equity (US) | — |
| AXSM | Axsome Therapeutics Inc | 1.05% | Equity (US) | — |
| IONS | Ionis Pharmaceuticals Inc | 0.98% | Equity (US) | — |
| MDGL | Madrigal Pharmaceuticals Inc | 0.88% | Equity (US) | — |
| SNY | Sanofi SA | 0.87% | Cash/Money Market | — |
| BMRN | BioMarin Pharmaceutical Inc | 0.86% | Equity (US) | — |
| ARWR | Arrowhead Pharmaceuticals Inc | 0.84% | Equity (US) | — |
| BNTX | BioNTech SE | 0.82% | Cash/Money Market | — |
| SMMT | Summit Therapeutics Inc | 0.82% | Equity (US) | — |
| KRYS | Krystal Biotech Inc | 0.76% | Equity (US) | — |
| NUVL | Nuvalent Inc | 0.73% | Equity (US) | — |
| TEM | Tempus AI Inc | 0.69% | Equity (US) | — |
| CYTK | Cytokinetics Inc | 0.69% | Equity (US) | — |
| HALO | Halozyme Therapeutics Inc | 0.67% | Equity (US) | — |
| ONC | BeOne Medicines Ltd | 0.67% | Cash/Money Market | — |
| ALKS | Alkermes PLC | 0.60% | Equity (US) | — |
| IBRX | ImmunityBio Inc | 0.60% | Equity (US) | — |
| PTGX | Protagonist Therapeutics Inc | 0.56% | Equity (US) | — |
| PRAX | Praxis Precision Medicines Inc | 0.56% | Equity (US) | — |
| PCVX | Vaxcyte Inc | 0.55% | Equity (US) | — |
| KYMR | Kymera Therapeutics Inc | 0.54% | Equity (US) | — |
| IMVT | Immunovant Inc | 0.54% | Equity (US) | — |
| SYRE | Spyre Therapeutics Inc | 0.51% | Equity (US) | — |
| ABVX | Abivax SA | 0.50% | Cash/Money Market | — |
| PTCT | PTC Therapeutics Inc | 0.50% | Equity (US) | — |
| MIRM | Mirum Pharmaceuticals Inc | 0.48% | Equity (US) | — |
| RYTM | Rhythm Pharmaceuticals Inc | 0.48% | Equity (US) | — |
| COGT | Cogent Biosciences Inc | 0.43% | Equity (US) | — |
Geographic Breakdown
Fund Holdings
Invesco Nasdaq Biotechnology ETF ·
NPORT-P period 2026-08-31
(filed 2026-04-28)
Net assets:
$76M
· 267 total positions
· equity 99.87%
· non-equity 19.89%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | Gilead Sciences, Inc. | 9.61% | $7.3M |
| 2 | Vertex Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | 9.30% | $7.0M |
| 3 | Amgen Inc. | Amgen Inc. | 9.12% | $6.9M |
| 4 | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. | 6.03% | $4.6M |
| 5 | Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals, Inc. | 3.28% | $2.5M |
| 6 | Insmed Inc. | Insmed Inc. | 2.38% | $1.8M |
| 7 | Biogen Inc. | Biogen Inc. | 2.10% | $1.6M |
| 8 | argenx SE, ADR | argenx SE | 1.67% | $1.3M |
| 9 | United Therapeutics Corp. | United Therapeutics Corp. | 1.62% | $1.2M |
| 10 | Moderna, Inc. | Moderna, Inc. | 1.56% | $1.2M |
| 11 | Illumina, Inc. | Illumina, Inc. | 1.53% | $1.2M |
| 12 | Roivant Sciences Ltd. | Roivant Sciences Ltd. | 1.50% | $1.1M |
| 13 | Incyte Corp. | Incyte Corp. | 1.49% | $1.1M |
| 14 | Royalty Pharma PLC, Class A | Royalty Pharma PLC | 1.47% | $1.1M |
| 15 | Revolution Medicines, Inc. | Revolution Medicines, Inc. | 1.47% | $1.1M |
| 16 | Viatris Inc. | Viatris Inc. | 1.28% | $973108 |
| 17 | Ascendis Pharma A/S, ADR | Ascendis Pharma A/S | 1.07% | $811179 |
| 18 | Neurocrine Biosciences, Inc. | Neurocrine Biosciences, Inc. | 0.98% | $746022 |
| 19 | Ionis Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. | 0.98% | $743577 |
| 20 | Sanofi, ADR | Sanofi | 0.96% | $729316 |
| 21 | BridgeBio Pharma, Inc. | BridgeBio Pharma, Inc. | 0.96% | $725829 |
| 22 | Medpace Holdings, Inc. | Medpace Holdings, Inc. | 0.95% | $719654 |
| 23 | Summit Therapeutics Inc. | Summit Therapeutics Inc. | 0.92% | $699667 |
| 24 | Guardant Health, Inc. | Guardant Health, Inc. | 0.91% | $687254 |
| 25 | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. | 0.89% | $671931 |
Showing top 25 of 264 equity holdings.
Non-equity holdings
— 3 positions,
19.89% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 19.89% | $15.1M | 3 |
Daily issuer data also available
(2026-06-13)
via ETF Constituents
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.24% | 5 |
| Feb | -0.85% | 5 |
| Mar | -0.41% | 5 |
| Apr | -1.80% | 5 |
| May | -0.51% | 5 |
| Jun | +1.25% | 6 |
| Jul | +3.33% | 5 |
| Aug | -0.28% | 5 |
| Sep | -3.68% | 5 |
| Oct | +1.45% | 5 |
| Nov | +1.91% | 5 |
| Dec | +1.64% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $29.17
SMA 50: $29.39
SMA 200: $27.95
Current: $29.57
EMA 12: $29.23
EMA 26: $29.26
MACD: -0.0248 | Signal: 0.0243
BEARISH
ADX (14): 9.33
RANGE
+DI: 24.48
−DI: 23.04
Momentum Oscillators
RSI (14): 53.05
NEUTRAL
Stoch %K: 59.83
Stoch %D: 51.05
Williams %R: -21.12
Volume & Volatility
BB Upper: $30.03
BB Lower: $28.31
NEUTRAL
OBV: 770,537
Vol SMA 20: 17,492
Vol ROC: -68.37%
ATR: $0.55
True Range: $0.36
HV 20: 27.4%
HV 30: 25.0%
HV 60: 24.2%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:15.300000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 33.18
- IV Rank (7D)
- 48.17
- Avg IV
- 39.1%
- Straddle (30D)
- $2.22
- Straddle (7D)
- $1.10
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.84
- Correlation (SPY)
- 51.9%
- R²
- 0.27
- Ann. Volatility
- 20.1%
- SPY Volatility
- 12.3%
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|